News from aidsmap

Sofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according to a report at the AASLD Liver Meeting in Washington, DC.

Read more >>

People with HIV less likely to be prescribed key drugs to reduce cardiovascular risk

Physicians in the United States are less likely to prescribe key recommended medications for the prevention of cardiovascular disease to people with HIV compared to HIV-negative individuals, according to research published in the Journal of the American Heart Association. Prescription rates for aspirin, antiplatelet medications and statins were markedly lower for people with HIV, all of whom presented with symptoms or risk factors for cardiovascular disease.

Read more >>

People with HIV who are undiagnosed and those with detectable viral load less likely to use condoms, South African study finds

People with HIV who don't use condoms consistently are more likely to be unaware they are HIV-positive or to have a detectable viral load when their HIV infection has been diagnosed, according to research conducted in South Africa and published in Nature Scientific Reports.

Read more >>

HIV-positive transgender men in US have significant unmet medical and social needs

HIV-positive transgender men in the United States have significant unmet social and healthcare needs, according to a study published in Research and Practice. Approximately half were living in poverty and only 60% had sustained viral suppression.

Read more >>

HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa

HIV drug resistance is increasing rapidly in southern and eastern Africa and Latin America and, as a result, it may soon be necessary to change the recommended first-line antiretroviral drug regimen in many countries to integrase inhibitor-based treatment, according to an analysis published in The Lancet Infectious Diseases on 30 November.

Read more >>

ART reduces prevalence of cervical infection with high-risk HPV, pre-cancerous cell changes and cervical cancer

Antiretroviral therapy (ART) is associated with a lower prevalence of high-risk cervical human papillomavirus (HPV) infection in women with HIV, according to the results of a meta-analysis published in The Lancet HIV. Prevalence of high-grade pre-cancerous HPV-related cervical lesions and invasive cervical cancer was also lower among ART users.

Read more >>

Many Americans still get their HIV diagnosis years after infection

Many people with HIV in the United States are still being diagnosed with HIV late, and therefore not getting the full therapeutic and prevention benefits of starting antiretroviral therapy (ART) early, according to the latest Vital Signs report from the US Centers for Disease Control and Prevention (CDC), released in advance of World AIDS Day.

Read more >>

HIV testing rate among children and adolescents boosted after caregivers receive a cash incentive

Children and adolescents are more likely to be tested for HIV if their parents or caregivers are offered a cash incentive, according to the results of a study conducted in Zimbabwe and published in The Lancet HIV. Offering the small cash incentive more than doubled the proportion of children undergoing testing.

Read more >>

More work and lower drug prices are needed to eliminate hepatitis C worldwide

Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do this more people need to be tested and treated and prices of direct-acting antivirals (DAAs) need to come down, according to presentations at the AASLD Liver Meeting in Washington, DC.

Read more >>

Editors' picks from other sources

Setting the standard: new prevention trials in the era of oral PrEP

from AVAC

There’s a lot going on in the world of HIV prevention research right now. One key issue is how participants might access oral pre-exposure prophylaxis (PrEP) as part of HIV prevention trials. It may seem simple: trial participants have the right to the highest standard of HIV prevention and care as part of participation. But the ethics, trial design issues and the mechanisms by which interventions are provided as standard of care are quite complex. Opinions differ and politics abound.

The most anti-gay corporate policy in America today

from GLAD

It’s time to end the anti-gay PrEP exclusion in America’s insurance industry. Some of the largest insurance companies in the nation exclude PrEP users who individually apply for life insurance, long-term care insurance or disability insurance.

Opinion: The UK needs stronger political leadership – and investment – to fight AIDS

from Devex

"The U.K. must increase its contributions to multilateral organizations working on the HIV response, including the Global Fund, UNAIDS, and UNITAID, if we are to meet the [Sustainable Development Goal (SDG)] target on AIDS. Beyond the financing, the U.K. also has a critical role to play in using its political leadership and global influence to promote and protect the rights of the groups at the greatest risk of being left behind."

Why is HIV prevention among young women and girls not working? We have forgotten the men

from Daily Maverick

Urgent action is needed on two fronts. The first is challenging and transforming harmful gender and social norms that discourage men from seeking health services and behaviours that increase the likelihood of HIV transmission to women and girls. The second is to ensure that health systems in general, and health service delivery specifically, are designed in a way that will meet men where they are with HIV-related services.

One year in: lessons on rolling out an HIV prevention pill in South Africa

from The Conversation

There is a high level of political will and desire in the government to rollout PrEP to young women who are at risk, but the health system requirements are complex. South Africa needs to pay careful attention to access and service delivery issues and constraints, and to engage communities as PrEP is scaled up so that its potential is fully realised.

Cuba’s HIV sanatoriums: prisons or public health tool?

from North American Congress on Latin America

An interview with Dr Jorge Pérez Ávila, former sanatorium director and renowned HIV expert, and medical anthropologist and activist Alfredo González, on Cuba’s controversial sanatorium system.